Ildong Holdings Co., Ltd. (000230.KS)
KRW 6600.0
(-5.44%)
KRW 6600.0
(-5.44%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 198.88 Billion KRW | -16.83% |
| 2022 | 239.12 Billion KRW | 8.28% |
| 2021 | 220.83 Billion KRW | -10.45% |
| 2020 | 246.59 Billion KRW | 113.09% |
| 2019 | 115.72 Billion KRW | 478.21% |
| 2018 | 20.01 Billion KRW | 10.17% |
| 2017 | 18.16 Billion KRW | 2.71% |
| 2016 | 17.68 Billion KRW | -92.53% |
| 2015 | 236.64 Billion KRW | 14.91% |
| 2014 | 205.94 Billion KRW | 1.45% |
| 2013 | 202.99 Billion KRW | 6.29% |
| 2012 | 190.98 Billion KRW | -4.24% |
| 2011 | 199.44 Billion KRW | 7.73% |
| 2010 | 185.13 Billion KRW | -16.67% |
| 2009 | 222.17 Billion KRW | 3.34% |
| 2008 | 214.99 Billion KRW | -1.69% |
| 2007 | 218.68 Billion KRW | 3.84% |
| 2006 | 210.59 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 60.18 Billion KRW | 11.66% |
| 2024 Q1 | 53.89 Billion KRW | 6.68% |
| 2024 Q3 | 166.56 Billion KRW | -5.05% |
| 2023 Q3 | 48.09 Billion KRW | -12.9% |
| 2023 Q2 | 55.22 Billion KRW | -0.21% |
| 2023 Q1 | 55.33 Billion KRW | -1.27% |
| 2023 Q4 | 50.52 Billion KRW | 5.04% |
| 2023 FY | 198.88 Billion KRW | -16.83% |
| 2022 FY | 239.12 Billion KRW | 8.28% |
| 2022 Q1 | 60.03 Billion KRW | 15.94% |
| 2022 Q2 | 61.27 Billion KRW | 2.07% |
| 2022 Q3 | 61.76 Billion KRW | 0.79% |
| 2022 Q4 | 56.04 Billion KRW | -9.25% |
| 2021 Q3 | 58.7 Billion KRW | 2.66% |
| 2021 Q4 | 51.78 Billion KRW | -11.8% |
| 2021 Q1 | 53.15 Billion KRW | -11.73% |
| 2021 Q2 | 57.18 Billion KRW | 7.58% |
| 2021 FY | 220.83 Billion KRW | -10.45% |
| 2020 Q4 | 60.22 Billion KRW | -2.65% |
| 2020 FY | 246.59 Billion KRW | 113.09% |
| 2020 Q1 | 54.7 Billion KRW | 9.81% |
| 2020 Q2 | 69.8 Billion KRW | 27.62% |
| 2020 Q3 | 61.86 Billion KRW | -11.38% |
| 2019 Q3 | 52.84 Billion KRW | 707.26% |
| 2019 FY | 115.72 Billion KRW | 478.21% |
| 2019 Q2 | 6.54 Billion KRW | 0.43% |
| 2019 Q4 | 49.81 Billion KRW | -5.73% |
| 2019 Q1 | 6.51 Billion KRW | 63.55% |
| 2018 Q3 | 6.17 Billion KRW | 23.93% |
| 2018 Q1 | 4.86 Billion KRW | 26.46% |
| 2018 FY | 20.01 Billion KRW | 10.17% |
| 2018 Q4 | 3.98 Billion KRW | -35.49% |
| 2018 Q2 | 4.98 Billion KRW | 2.45% |
| 2017 Q3 | 4.42 Billion KRW | -6.05% |
| 2017 Q2 | 4.71 Billion KRW | -9.03% |
| 2017 Q1 | 5.17 Billion KRW | 69.79% |
| 2017 FY | 18.16 Billion KRW | 2.71% |
| 2017 Q4 | 3.84 Billion KRW | -13.08% |
| 2016 Q4 | 3.05 Billion KRW | -23.82% |
| 2016 FY | 17.68 Billion KRW | -92.53% |
| 2016 Q3 | 4 Billion KRW | -27.88% |
| 2016 Q2 | 5.55 Billion KRW | -91.09% |
| 2016 Q1 | 62.29 Billion KRW | -0.43% |
| 2015 FY | 236.64 Billion KRW | 14.91% |
| 2015 Q1 | 58.39 Billion KRW | -0.77% |
| 2015 Q2 | 56.56 Billion KRW | -3.15% |
| 2015 Q3 | 59.11 Billion KRW | 4.52% |
| 2015 Q4 | 62.56 Billion KRW | 5.84% |
| 2014 Q4 | 58.85 Billion KRW | 12.62% |
| 2014 Q3 | 52.25 Billion KRW | 3.63% |
| 2014 Q2 | 50.42 Billion KRW | 13.57% |
| 2014 Q1 | 44.4 Billion KRW | -21.82% |
| 2014 FY | 205.94 Billion KRW | 1.45% |
| 2013 FY | 202.99 Billion KRW | 6.29% |
| 2013 Q4 | 56.79 Billion KRW | 6.32% |
| 2013 Q1 | 45.67 Billion KRW | -13.74% |
| 2013 Q3 | 53.42 Billion KRW | 13.42% |
| 2013 Q2 | 47.1 Billion KRW | 3.12% |
| 2012 FY | 190.98 Billion KRW | -4.24% |
| 2012 Q4 | 52.95 Billion KRW | 11.55% |
| 2012 Q3 | 47.46 Billion KRW | -6.98% |
| 2012 Q2 | 51.03 Billion KRW | 30.91% |
| 2012 Q1 | 38.98 Billion KRW | 0.0% |
| 2011 FY | 199.44 Billion KRW | 7.73% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 48.08 Billion KRW | -4.09% |
| 2011 Q1 | 48.57 Billion KRW | 0.0% |
| 2011 Q2 | 50.13 Billion KRW | 3.22% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 185.13 Billion KRW | -16.67% |
| 2010 Q3 | 49.32 Billion KRW | 16.71% |
| 2010 Q2 | 42.26 Billion KRW | 0.0% |
| 2009 FY | 222.17 Billion KRW | 3.34% |
| 2009 Q2 | 42.66 Billion KRW | 0.0% |
| 2009 Q3 | 47.89 Billion KRW | 12.25% |
| 2009 Q4 | 50.17 Billion KRW | 4.78% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 Q4 | 41.92 Billion KRW | -10.27% |
| 2008 Q2 | 41.96 Billion KRW | 0.0% |
| 2008 Q3 | 46.72 Billion KRW | 11.33% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 FY | 214.99 Billion KRW | -1.69% |
| 2007 Q3 | 42.94 Billion KRW | 9.95% |
| 2007 FY | 218.68 Billion KRW | 3.84% |
| 2007 Q4 | 40.03 Billion KRW | -6.77% |
| 2007 Q2 | 39.05 Billion KRW | 0.0% |
| 2006 FY | 210.59 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -327.668% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 45.377% |
| HANDOK Inc. | 151.36 Billion KRW | -31.394% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -195.855% |
| Yuhan Corporation | 564.5 Billion KRW | 64.768% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 38.274% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -737.522% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 76.206% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -165.043% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 0.038% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -389.272% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -110.428% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -41.199% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -327.668% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -472.901% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -158.906% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1751.116% |
| JW Holdings Corporation | 446.15 Billion KRW | 55.422% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 4.169% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 69.651% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 40.75% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -152.973% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -164.344% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -175.423% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -8.2% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -327.668% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 32.608% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 70.818% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 40.75% |
| Yuhan Corporation | 564.5 Billion KRW | 64.768% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 1.454% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -180.363% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -100.841% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 40.75% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -36.325% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -14.64% |
| CKD Bio Corp. | 5.01 Billion KRW | -3869.562% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 21.769% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -8.018% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -102.687% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -152.973% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 46.463% |
| Boryung Corporation | 333.26 Billion KRW | 40.322% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -297.412% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 0.038% |
| JW Lifescience Corporation | 51.32 Billion KRW | -287.505% |